Capchase Secures $200M+, as Demand for Vendor Financing in Enterprise Tech Deals Accelerates
27.5.2026 16:00:00 CEST | Business Wire | Press Release
Capchase, the leading vendor financing platform for enterprise tech, today announced $200M+ in incremental funding to scale its embedded financing infrastructure globally and deploy more AI-enabled features.
The funding, a mix of debt warehouse facilities and equity backed by institutional investors, reflects market validation that vendor financing has become essential infrastructure for enterprise technology companies to sell hardware and software products. As global B2B buyers face tighter budgets and greater scrutiny over large, up-front purchases, financing demand is growing.
The Market Shift: Financing as a Growth Lever for B2B Tech Companies
The $1.3 trillion vendor financing market has been traditionally dominated by banks and other lenders that utilize multi-thread email chains to manual doc review for underwriting.
Capchase replaces those bottlenecks with financing tech embedded directly into sales tools such as Salesforce, enabling 97% of lending applications to be vetted and decisioned in under 30 seconds.
“For a cybersecurity company like Barracuda, the ability to offer customers flexible subscription financing, with and through our partner ecosystem — without the delays of traditional lenders — directly translates to faster deal cycles and stronger customer relationships. Capchase has become a genuine competitive advantage for our channel.”
— Geoff Waters, CRO, Barracuda Networks
In today’s macroeconomic environment, buyers face budget constraints and tighter cash controls from their CFOs, who prioritize cash preservation over sales enablement. Capchase helps sales leaders access the tech they need without requiring large, upfront payments or waiting for the customer’s next budget approval cycle.
“What we look for in a financing partner is straightforward: they need to move at the speed of the channel. Capchase does exactly that. Quotes turn into approvals in minutes—not days—and that velocity carries through to our sellers and our clients. That’s the standard partners should be held to in 2026.”
— Rob Zack, Vice Chair, MicroAge
The Only Salesforce-Native Financing Platform for Enterprise Tech Vendors
Capchase is the only platform that’s both the lender and the lending infrastructure. Banks have capital but lack speed and software. SaaS and POS partners don’t lend capital directly. Capchase offers both at the speed of tech.
"We moved away from our previous financing provider when it became clear they couldn’t match the speed, technology, or certainty of funding that Capchase offers. What once required hours of forms, email chains, and back-and-forth with customers now happens in minutes directly within Salesforce. Financing used to be a friction point in our sales motion. With Capchase, it became a growth driver."
— Stephanie Southard, Head of Sales, Datarails
AI-Enabled Underwriting & Lending: From Days to Minutes
Capchase AI powers core platform functionality such as underwriting, proposals, purchase order generation, and deal management workflows. But today, Capchase launches a new AI-native product to further streamline the financing process.
Our Agentic Lending Coordinator collects quotes, POs, emails, and other documents, and converts them into an executable loan package instantly. It then manages multi-party collaboration between vendors, partners, and buyers from package review through signing. Since the beta launch, Capchase customers have seen an 8-hour process condensed into a 60-second automation.
Fortune 500 Tech Companies Run on Capchase’s Financing Infrastructure
Capchase’s category leadership is reflected in its growing customer ecosystem, including Barracuda (mission-critical cybersecurity platforms), CDW and Insight (the largest IT solution providers in North America), and MicroAge (which extends financing to the mid-market segment via the reseller channel).
These partnerships highlight where financing demand is strongest: multi-party enterprise tech deals where speed determines outcomes.
“Traditional financing lenders have capital but lack technology, speed, and scale. By becoming both the lender and the infrastructure for vendor financing, we’re making it a growth lever for sales teams, rather than a bottleneck.”
— Miguel Fernandez, CEO & Co-Founder, Capchase
About Capchase
Capchase is a vendor financing platform and lender that helps enterprise technology companies close more deals by offering instant financing to their buyers. We’ve transformed the vendor financing process by embedding underwriting, origination, and deal management directly into sales workflows, and generating loan proposals and documents with the help of AI agents.
Founded in 2020, Capchase serves enterprise tech companies and channel partners, including Barracuda, Verkada, Motive, Okta, Datarails, CDW, Netradyne, and Insight. Capchase is based in New York, with offices in San Francisco and Madrid, and is backed by leading fintech investors QED, Invesco, Thomvest, and 01 Advisors.
Vendor financing at the speed of tech.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260527647157/en/
Contacts
Media contact: Ally Basak, Kindling Collective
415-990-8370
ally@kindling-collective.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 16:50:00 CEST | Press Release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive
emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 17:12:00 CEST | Press Release
emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead
Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 15:00:00 CEST | Press Release
Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme
EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 15:00:00 CEST | Press Release
European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 14:00:00 CEST | Press Release
ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom